Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$4.15 USD
+0.06 (1.47%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $4.16 +0.01 (0.24%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Aldeyra Therapeutics, Inc. (ALDX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.33 | $11.00 | $7.00 | 128.12% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Aldeyra Therapeutics, Inc. comes to $9.33. The forecasts range from a low of $7.00 to a high of $11.00. The average price target represents an increase of 128.12% from the last closing price of $4.09.
Analyst Price Targets (6 )
Broker Rating
Aldeyra Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ALDX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/9/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
4/3/2024 | Not Identified | Not Identified | Hold | Strong Buy |
4/2/2024 | H.C. Wainwright & Co. | Matthew Caufield | Not Available | Strong Buy |
1/7/2024 | BTIG | Thomas Shrader | Not Available | Strong Buy |
10/17/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $9.33 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 97 of 252 |
Current Quarter EPS Est: | -0.14 |